Nonresectable hepatocellular carcinoma: Long-term toxicity in patients treated with transarterial chemoembolization-single-center experience 1

Radiology

Volumn 249, Issue 1, 2008, Pages 346-354

  Buijs, Manon ^a   Vossen, Josephina A ^a   Frangakis, Constantine ^a   Hong, Kelvin ^a   Georgiades, Christos S ^a   Chen, Yong ^a   Liapi, Eleni ^a   Geschwind, Jean François H ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; MITOMYCIN C; MUTAMYCIN C; UNCLASSIFIED DRUG; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOEMBOLIZATION; DATA BASE; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; ADOLESCENT; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; LIVER TUMOR; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ALOPECIA; ANEMIA; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; LEUKOPENIA; LIVER NEOPLASMS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 53749085999     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2483071902     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
3. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006;15:1198-1203.
4. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-524.
5. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
6. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004;127(5 suppl 1):S218-S224.
7. Chung JW, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198:33-40.
8. Xia J, Ren Z, Ye S, et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol 2006;59:407-412.
9. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
10. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
12. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37(suppl 2):S88-S94.
13. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007;102:1661-1670.
14. Stuart KE, Anand AJ, Jenkins RL. Hepato- cellular carcinoma in the United States: prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-2222.
15. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969-977.
16. Barone M, Ettorre GC, Ladisa R, et al. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology 2003;50:183-187.
17. Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer 1994;74:16-24.
18. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-184.
19. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-1583.
20. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001;28:503-513.
21. DiMaio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002;35(5 suppl 2):S109-S114.
22. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
23. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. AnnOncol1997;8:117-136.
24. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 1988;62:479-483.
25. Gunnars B, Nygren P, Glimelius B. Assessment of quality of life during chemotherapy. Acta Oncol 2001;40:175-184.
26. RidderheimM, Bjurberg M, Gustavsson A. Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 2003;11:371-377.
27. Fischer DS, Knobf MT, Durivage HJ. The cancer chemotherapy handbook. 4th ed. St. Louis, Mo: Mosby, 1993.
28. Kiely JM, Rilling WS, Touzios JG, et al. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol 2006;17:47-53.
29. Caturelli E, Siena DA, Fusilli S, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 2000;215:123-128.
30. Geschwind JF, Ramsey DE, Choti MA, Thuluvath PJ, Huncharek MS. Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am J Clin Oncol 2003;26:344-349.
31. Ikeda M, Okada S, Yamamoto S, et al. Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Jpn J Clin Oncol 2002;32:455-460.
32. Llado L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88:50-57.
33. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: metaanalysis of randomized controlled trials. Radiology 2002;224:47-54.
34. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16:1653-1659.
35. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.